Role of Chromosome 3q Amplification in Lung Cancer

Slides:

Advertisements

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Advertisements

Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Volume 111, Issue 6, Pages (June 1997)

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

High-Risk Human Papillomavirus–Positive Lung Cancer: Molecular Evidence for a Pattern of Pulmonary Metastasis Robert A.A. van Boerdonk, MSc, Johannes.

Volume 52, Issue 1, Pages (July 2007)

Tracy I. George, Joanna E. Wrede, Charles D. Bangs, Athena M

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies Sandra Salvi, PhD, Serena Varesano, PhD, Simona.

Establishment and Expression Profiling of New Lung Cancer Cell Lines from Chinese Smokers and Lifetime Never-Smokers David C.L. Lam, MBBS, Luc Girard,

Carmo Martins, Branca Cavaco, Giovanni Tonon, Frederic J

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

ALK FISH and IHC: You Cannot Have One without the Other

TGM2: A Cell Surface Marker in Esophageal Adenocarcinomas

Mariëlle I. Gallegos Ruiz, MSc, Hester van Cruijsen, MD, Egbert F

Timon P. H. Buys, BSc, Sarit Aviel-Ronen, MD, Thomas K

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

Fluorescence In Situ Hybridization

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer Marta Salido, MSc, Lara Pijuan, MD, PhD, Luz Martínez-Avilés,

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive.

Interpretation of Anti-ALK Immunohistochemistry Results

Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

Genomewide DNA Methylation Analysis Identifies Novel Methylated Genes in Non– Small-Cell Lung Carcinomas Rejane Hughes Carvalho, PhD, Jun Hou, PhD, Vanja.

Comprehensive Hybrid Capture–Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative.

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Marleen J. ter Avest, BSc, Romane M. Schook, MD, Pieter E

Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study Anne McLeer-Florin, PhD, Denis Moro-Sibilot,

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung Anna Caliò, MD, Alessia Nottegar, MD, Eliana Gilioli, MD, Emilio Bria, MD, Sara.

Detection of Human Polyomavirus 7 in Human Thymic Epithelial Tumors

Searching for ROS1 Rearrangements in Lung Cancer by Fluorescent In Situ Hybridization: The Importance of Probe Design Arnaud Uguen, MD, Pascale Marcorelles,

High-Risk Human Papillomavirus–Positive Lung Cancer: Molecular Evidence for a Pattern of Pulmonary Metastasis Robert A.A. van Boerdonk, MSc, Johannes.

Chromosomal Abnormalities in Non-Small Cell Lung Carcinomas and in Bronchial Epithelia of High-Risk Smokers Detected by Multi-Target Interphase Fluorescence.

Increased Vascular-Endothelial Growth Factor (VEGF) Tumor Expression and Response to Epidermal Growth Factor Receptor (EGF-R) Inhibitor Erlotinib in Non-small.

NUT Midline Carcinoma: An Aggressive Intrathoracic Neoplasm

Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer Patrick Micke, MD, PhD, Karolina Edlund,

“The Best-Laid Plans … Often go Awry …”

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

The Prognostic Significance of Focal Adhesion Kinase Expression in Stage I Non– Small-Cell Lung Cancer Grace K. Dy, MD, Lourdes Ylagan, MD, Saraswati.

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors

High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer Yan Feng, MD, Eugen C. Minca, MD,

Gayatry Mohapatra, Rebecca A. Betensky, Ezra R

Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas Scott W. Aesif, MD,

Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method.

Amplification of MET in a Patient with Malignant Pleural Mesothelioma

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,

Genome–Wide Hypomethylation and Specific Tumor-Related Gene Hypermethylation are Associated with Esophageal Squamous Cell Carcinoma Outcome Sojun Hoshimoto,

Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Genetic Changes in Squamous Cell Lung Cancer: A Review

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Ethnic Differences in the Management of Lung Cancer in New Zealand

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

A, heatmap of copy number alterations determined by array CGH for a panel of 79 frozen NSCLC samples. A, heatmap of copy number alterations determined.

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

A Review of First-Line Treatment for Small-cell Lung Cancer

Presentation transcript:

Role of Chromosome 3q Amplification in Lung Cancer Jun Qian, PhD, Pierre P. Massion, MD Journal of Thoracic Oncology Volume 3, Issue 3, Pages 212-215 (March 2008) DOI: 10.1097/JTO.0b013e3181663544 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A, Whole genome analysis of a severe dysplastic lesion on a 32,000 Human BAC Tiling-Path Array (UCSF Cancer Center Array Core). A log2 signal ratio of 0 represents equivalent copy number between the sample and the reference sex matched DNA. Each dot represents a single BAC clone normalized hybridization ratio. Chromosomal boundaries are indicated by vertical lines. Chromosome 3q amplification is magnified in rectangle. B, A map of the 3q26–28 cytobands showing 15 genes that were previously published. C, Dual color FISH of TP73L (p63) gene (3q28, red spots) and a FHIT probe on the opposite arm of the same chromosome (3p14.2, green spots) on a squamous carcinoma of the lung tissue sample. In squamous carcinoma cells, interphase nuclei show amplification of the p63 gene. D, p63 Immunohistochemical analysis with 4A4 antibody in lung tumorigenesis. Bronchial epithelium shows immunostaining at the basal layer. Severe dysplasia of the bronchial epithelium shows a progressive increase of p63 immunostaining from the basal layer to the surface of the epithelium. Squamous carcinoma shows strong staining for the majority of the tumor cells. Journal of Thoracic Oncology 2008 3, 212-215DOI: (10.1097/JTO.0b013e3181663544) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions